Danish/Australian co-operation to improve TB (tuberculosis) diagnosis
This article was originally published in Clinica
Executive Summary
The Danish State Serum Institute (SSI) and the Australian biotechnology company Cellestis, have entered into an agreement to jointly develop tuberculosis diagnosis technology. The agreement will grant the Melbourne-based company exclusive rights to SSI's TB specific protein, to use in its QuantiFERON diagnostic technology.